Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 will impact only patented and branded products, not generic medicines.
Hyderabad, Mar 28 (PTI) Dr Reddy's Laboratories Limited has launched Levocetirizine tablets (5mg), a bio-equivalent generic version of Xyzal tablets in the USA market, the company said on Monday.
According to Dr Reddy's, the drugmaker may launch Rivastigmine, an anti-mild-to-moderate Alzheimer's drug, Desloratadine, used to treat allergies and Pseudoephedrine, a nasal/sinus decongestant.
Hyderabad-based Dr Reddy's Laboratory said on Wednesday it has launched the generic version of Merck & Co's prostate cancer drug Proscar in the US market after the expiry of its patent.
Concerns over weakening demand for Indian pharmaceutical (pharma) drugs in the US - their largest export market - have weighed heavily on investor sentiment this year. While the Nifty 50 has gained 6.02 per cent year - to - date (as on September 15), the Nifty Pharma index has declined 5.18 per cent, National Stock Exchange data shows.
Dr Reddy's Laboratories Ltd filed a lawsuit seeking declaratory judgement against Pfizer in United States District Court for the District of New Jersey regarding its Abbreviated New Drug Application for Sertraline HCl.
The Hyderabad-based drugmaker said consolidated net profit rose to Rs Rs 361 crore (Rs 3.61 billion) for the fiscal first quarter ended June, from Rs 336 crore (Rs 3.36 billion) a year earlier.
US accounts for a large part of revenue for top Indian pharma companies like Gland Pharma (54 percent), Dr Reddy's (53 per cent), and Aurobindo Pharma (48 per cent).
In a bid to speed up the litigation process, the leading home-grown pharma company Dr Reddy's Laboratories has withdrawn its challenge against GlaxoSmithKline's "compound" patent for anti-nausea drug Zofran.
Indian drugmaker Dr Reddy's Laboratories Ltd said on Wednesday it has filed with the US Food and Drug Administration to market a generic version of Aventis Pharmaceuticals' anti-allergy drug Allegra.
Pharma major Dr Reddys Laboratories has voluntarily recalled 78,876 bottles of 2mg and 4mg Risperidone, generic version of Resperdal, tablets in the United States.
Dr Reddy's Laboratories said on Thursday Novartis has decided to stop further work on an anti-diabetes compound licensed to the Swiss drug maker, the second time in six months that a foreign partner has halted development of the Indian firm's drugs.
Dr Reddy's Laboratories received a major setback in the US, as a court there granted a motion seeking a preliminary injunction to block the launch of its generic version of Sanofi-Aventis' anti-allergic drug, Allegra D24.
Sunovion Pharmaceuticals Inc is the owner of the Eszopiclone drug.
Dr Reddy's Laboratories hopes to become a true drug discovery company in the near future, said chairman K Anji Reddy and chief executive officer GV Prasad at the 24th annual general body meeting in Hyderabad on Tuesday.
Dr Reddy's Laboratories is setting up two special economic zones -- one each at Hyderabad and Visakhapatnam in Andhra Pradesh.
Asian markets were trading mixed with the Nikkei gaining after the US dollar strengthened against the yen.
Suit alleges fraud by hiding significant deficiencies in CGMP regulations enforced by US health regulator.
The FDA has been tightening its monitoring of Indian pharma majors over compliance issues. Surprise plant inspections and import alerts have been frequent outcomes
"Dr Manmohan Singh, soon after becoming the prime minister, had himself carried a small table for us to have tea comfortably at his Safdarjung Lane residence instead of asking his house help," Dr Srinath Reddy, who was the chairperson of the PM's medical panel, recalled.
Dr Reddy's Laboratories Ltd on Friday said it has received tentative approval from US Food and Drug Administration for amlodipine besylate tablets.
Dr Reddy's Laboratories on Monday said it has, for the first time, started testing a drug in Europe with the initiation of Phase I clinical trials for its cardiovascular drug candidate RUS 3108 in Belfast, Ireland.
P B Jayakumar caught up Dr Reddy's chairman K Anji Reddy and tried to balance science and religion. And yes, there is also the question of choosing between the son and the son-in-law.
Pharma major Dr Reddy's Laboratories, on Monday said it will offer MBA programme in pharma management for its employees in association with Narsee Monjee Institute of Management Studies, Mumbai.
The collaboration will work on a profit sharing model and entail licensing of manufacturing know-how of products by DRL, local manufacturing of products in Russia, co-development of high technology products and knowledge sharing between both parties at regular intervals.
Take the Rediff Biz Quiz and find out how much you know about India Inc's merger and acquisition operatiosns.
The Drug Controller General of India (DCGI) has sought clarification from pharma majors Dr Reddy's Laboratories and Mumbai-based Piramal Healthcare, for allegedly sponsoring doctors for conferences.
Dr Reddy's Laboratories Limited announced on Thursday that the United States Food and Drug Administration has issued final approval for the company's abbreviated New Drug Application for Ciprofloxacin tablets 100 mg, 250 mg, 500 mg and 750 mg.
Analysts are eyeing bigger launches that will positively impact company's fortunes.
Trading sentiment in the stock market this week will be guided by quarterly earning announcements from blue-chips such as Infosys and Bajaj Finance, the outcome of India-US trade talks and global cues, analysts said. Markets may on Monday react to the quarterly results of three heavyweights - Reliance Industries, HDFC Bank and ICICI Bank, an expert said.
Dr Reddy's Laboratories, the country's second biggest drug maker, revealed an unexpected consolidated net loss of Rs 522 crore in the October-December quarter, due to a writedown of intangible assets and goodwill in its German arm, Betapharm.
The US drug regulator raised the issue of significant deviations from the current good manufacturing practice (cGMP) in three of DRRD's plants in a letter issued in November 2015
